1 Here we describe a detailed protocol based on covalent bindin
2 Here we describe a detailed protocol that describes how to in
3 Here we describe a measurement platform that allows for the c
4 Here we describe a medicinal chemistry program starting from
5 Here we describe a microfluidic DNA preconcentration techniqu
6 Here we describe a molecular system that can be programmed to
7 Here we describe a new, exquisitely three-dimensionally prese
8 Here we describe a parasite-specific transcription factor PfA
9 Here we describe a phosphoproteomics workflow to examine the
10 Here we describe a platform for identifying target-binding cy
11 Here we describe a protocol to generate expandable and multip
12 Here we describe a reporter cell-based assay to quantify indu
13 Here we describe an enhanced fluorescence fluctuation imaging
14 Here we describe an optimized protocol for simultaneous dual-
15 Here we describe an update of the database.
16 Here we describe DeActs, genetically encoded actin-modifying
17 Here we describe experiments in which we studied binocular in
18 Here we describe genome-engineering based evaluation of RNA r
19 Here we describe high-quality draft genomes of these two spec
20 Here we describe how to apply CellNet to RNA-seq data and how
21 Here we describe RCB-185, a lipophilic prodrug with nanomolar
22 Here we describe SGN-CD19B, a pyrrolobenzodiazepine (PBD)-bas
23 Here we describe ShootingStar, a platform for perturbation an
24 Here we describe the 'Asgard' superphylum, a group of unculti
25 Here we describe the interaction of myosin-5B with F-actin, n
26 Here we describe the stabilization of the heaviest 4+ ion of
27 Here we describe the temporal orchestration of a series of me
28 Here we described and analyzed a similar phenotype in POMT mu
29 Here, we describe a combined biological/enzymatic synthesis t
30 Here, we describe a CRISPR affinity purification in situ of r
31 Here, we describe a family with Liddle syndrome due to a muta
32 Here, we describe a generalizable platform to create dual-FP
33 Here, we describe a high-throughput method for rapid identifi
34 Here, we describe a hybrid platform combining common analysis
35 Here, we describe a mouse strain lacking the E3 ubiquitin lig
36 Here, we describe a rapid, inexpensive, and portable strategy
37 Here, we describe a structure we refer to as the embryo sheat
38 Here, we describe a study done in the Lake Superior-Saint Lou
39 Here, we describe a unique role for the orphan catalytic subu
40 Here, we describe an automated clustering approach and associ
41 Here, we describe B cell responses to C-PfCSP from European d
42 Here, we describe functional units, at a cellular level, of a
43 Here, we describe how F-specific antibodies protect against R
44 Here, we describe mGluR5 findings in stress disorders, partic
45 Here, we describe potential biases that arise when ABM assump
46 Here, we describe site-selective, copper-promoted couplings o
47 Here, we describe the development of an alternative vaccine s
48 Here, we describe the FEP+ method as applied to protein stabi
49 Here, we describe the map-based cloning of the Ms2 gene and s
50 Here, we describe two brothers with hematopoietic and immunol